PMID- 22411078
OWN - NLM
STAT- MEDLINE
DCOM- 20130111
LR  - 20151119
IS  - 1098-1101 (Electronic)
IS  - 0733-2459 (Linking)
VI  - 27
IP  - 4
DP  - 2012
TI  - The role of therapeutic apheresis in the treatment of acute antibody-mediated 
      kidney rejection.
PG  - 173-7
LID - 10.1002/jca.21211 [doi]
AB  - Approximately 10% of renal transplant recipients experience acute 
      antibody-mediated rejection (AMR) due to alloimmunization against human leukocyte 
      antigen (HLA) molecules and other antigens. While therapeutic apheresis is 
      included in most treatment protocols for acute kidney allograft rejection, these 
      protocols have been derived mainly from single center experience rather than 
      controlled trials. This concise review focuses on the role of therapeutic 
      apheresis in AMR treatment. Two groups have recently reported treating acute AMR 
      using drug-only strategies without therapeutic apheresis in particular 
      situations, namely in clinically less severe cases or in resource-limited 
      situations without testing for donor specific antibodies. A randomized controlled 
      trial, designed to test the efficacy of immunoadsorption apheresis in AMR 
      treatment, was terminated early and suggested a benefit of apheresis. An 
      observational study suggested efficacy of plasmapheresis in acute AMR treatment, 
      but all patients who received plasmapheresis also received rituximab. As new 
      therapeutic modalities are becoming available, therapeutic apheresis continues to 
      play a role in the treatment of acute kidney allograft rejection.
CI  - Copyright (c) 2012 Wiley Periodicals, Inc.
FAU - Ahmed, Tahmeena
AU  - Ahmed T
AD  - Department of Pathology, Stony Brook University Medical Center, Stony Brook, New 
      York 11794-7300, USA. tahmeena.ahmed@sbumed.org
FAU - Senzel, Lisa
AU  - Senzel L
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120313
PL  - United States
TA  - J Clin Apher
JT  - Journal of clinical apheresis
JID - 8216305
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Isoantibodies)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Acute Disease
MH  - Antibodies, Monoclonal, Murine-Derived/therapeutic use
MH  - Blood Component Removal/*methods
MH  - Graft Rejection/*etiology/immunology/*therapy
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Immunosorbent Techniques
MH  - Immunosuppressive Agents/therapeutic use
MH  - Isoantibodies/isolation & purification
MH  - Kidney Transplantation/*adverse effects/immunology
MH  - Plasmapheresis
MH  - Randomized Controlled Trials as Topic
MH  - Rituximab
MH  - Tissue Donors
EDAT- 2012/03/14 06:00
MHDA- 2013/01/12 06:00
CRDT- 2012/03/14 06:00
PHST- 2011/12/09 00:00 [received]
PHST- 2012/01/30 00:00 [accepted]
PHST- 2012/03/14 06:00 [entrez]
PHST- 2012/03/14 06:00 [pubmed]
PHST- 2013/01/12 06:00 [medline]
AID - 10.1002/jca.21211 [doi]
PST - ppublish
SO  - J Clin Apher. 2012;27(4):173-7. doi: 10.1002/jca.21211. Epub 2012 Mar 13.